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Abstract 
 
 
Aim 
This review aimed to compare the efficacy and safety of short-term (=< 3 months) and long-term (>=1 year) 
dual-antiplatelet therapy (DAPT) in secondary prevention for ischaemic stroke. 
 
Methods and results  
We searched MEDLINE, EMBASE (Ovid), PubMed, Cochrane Library, ClinicalTrials.gov and Google Advanced 
Search for randomised controlled trials. The population consisted of patients with recent ischaemic stroke or 
transient ischaemic attack. The intervention was DAPT with a combination of aspirin, clopidogrel and 
dipyridamole compared to either aspirin or clopidogrel in monotherapy. The primary outcome was the rate of all 
recurrent stroke (ischaemic and haemorrhagic). Secondary outcomes were ischaemic stroke, all bleeding, 
severe bleeding, all-cause death, cardiovascular death and myocardial infarction. Data were pooled by network 
metanalysis and pairwise metanalyses. 
 
Sixteen studies with 55,261 participants were included. Compared to aspirin, DAPT with aspirin clopidogrel 
decreased the risk of recurrent stroke (short-term OR 0.67, 95%CI 0.58-0.77; long-term OR 0.84, 95%CI 0.70-
1.01) at the expense of increased risk of bleeding (short-term OR 1.76, 95%CI 1.26-2.46; long-term OR 2.25, 
95%CI 1.97-2.57). DAPT with aspirin clopidogrel and clopidogrel in monotherapy had similar long-term risk of 
recurrent stroke (OR 0.98, 95%CI 0.83-1.14), but DAPT was associated with increased risk of bleeding (OR 
2.77, 95%CI 2.21-3.46). Network metanalysis showed that short-term aspirin clopidogrel DAPT had the best 
risk-benefit profile, followed by long-term aspirin clopidogrel DAPT and clopidogrel alone. Aspirin dipyridamole 
DAPT was less effective.  
 
Conclusion 
Short-term DAPT had better risk-benefit profile than long-term DAPT.  
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Introduction 
 
 
Dual anti-platelet therapy (DAPT) with aspirin, clopidogrel or dipyridamole in combination is established in the 
management of ischaemic stroke. There is however uncertainty on the optimal duration of DAPT for the 
secondary prevention of stroke.  
 
Guidance from the AHA/ASA (1) supports the use of DAPT for 21 days or for a period of up to 90 days from 
symptoms onset. The class of recommendation (IIa) and level of evidence (B) are both moderate. The UK 
NICE guidance (2) is even more vague as it states that people who have had an ischaemic stroke or transient 
ischaemic attack (TIA) should be treated with clopidogrel or dipyridamol in monotherapy or in combination with 
aspirin (DAPT) with an “option to continue treatment until they and their clinicians consider it appropriate to 
stop”.  
 
No trials have compared short vs. long-term DAPT in this context. The rationale of this review was to highlight 
indirect evidence on the comparative efficacy of short-term vs long-term DAPT by performing a network 
metanalysis. 
 
The research question and objective were framed as follows (PICOS acronym) (3): in patients with ischaemic 
stroke or TIA (P = population), short-term DAPT (<3 months), long-term DAPT (>= 1 year) (I = intervention) and 
monotherapy (either aspirin or clopidogrel) (C = comparison) were evaluated. Prevention of recurrent stroke 
was the primary efficacy measure (O = outcome). Prevention of ischaemic stroke, all bleeding, severe bleeding, 
all-cause death, cardiovascular death and myocardial infarction were secondary outcomes. Evidence was 
derived from randomized controlled trials (RCTs) (S = study design).  
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Methods 
 
Participants 
We identified RCTs with results in English comparing antiplatelet monotherapy vs. DAPT (aspirin, clopidogrel, 
dipyridamole) in adult (>17 years) patients with a previous ischaemic stroke or transient ischaemic attack (TIA), 
for the secondary prevention of stroke. Studies of patients receiving intra-arterial treatment, with acute 
myocardial infarction, coronary artery stenting or coronary artery bypass grafting, with atrial fibrillation, 
prosthetic heart valves or congenital conditions were excluded.  
 
Interventions 
Aspirin clopidogrel and aspirin dipyridamole vs either aspirin or clopidogrel monotherapy were included. Triple 
antiplatelet treatment, as well as trials evaluating placebo are losing importance in contemporary practice and 
were excluded. 
 
Outcome measures 
The observation and follow-up period had to be >= 7 days, i.e. beyond the immediate management of stroke. 
Trials were categorized into short-term (treatment and follow-up up to 3 months) and long-term (equal to or 
longer than 1 year), based on contemporary consensus as in practice guidelines (1). The rate of recurrent 
stroke was evaluated as primary outcome, including ischaemic, haemorrhagic and fatal and nonfatal stroke. 
Ischaemic stroke, all-cause death, cardiovascular death and myocardial infarction were secondary efficacy 
outcomes. All bleeding and severe bleeding were safety outcomes (definitions in Table S1). Only RCTs 
reporting at least one of these clinical outcomes were considered. RCTs reporting only aggregate or surrogate 
outcomes were excluded. 
 
Electronic searches 
MEDLINE, EMBASE (Ovid), PubMed, Cochrane Library, ClinicalTrials.gov were searched for RCTs up to 15 
August 2018, with restriction to Human studies in English language. Search strategy/terms are shown in Table 
S2. Google Advanced Search was used for relevant grey literature. References from articles, reviews and 
study protocols were manually checked.  
 
Selection 
Studies were independently searched and selected by two Authors (FP and PA). Cases of disagreement were 
discussed in consensus involving the other two Authors (MM and SD). References were rejected if it could be 
determined from the title/abstract that they were not suitable. Full text was obtained in all other cases. 
 
Data extraction 
 General: title, authors, report/publication year, duplicate publication  
 Participants: total number and number in comparison groups, age, similarity at baseline, losses to follow-up 
 Intervention and Comparison: drug name, treatment onset since qualifying stroke, duration of 
treatment/follow-up, dose 
 Outcome: recurrent stroke and secondary outcomes (Table S1) 
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 Study design and characteristics: duration, allocation concealment, blinding, intention-to-treat (ITT) analysis, 
loss to follow-up 
 
Risk of bias within studies 
Within-study risk of bias (4) was assessed according to criteria defined in the Risk of Bias tool (RoB2.0) (5) 
using free software (RevMan 5.2). Commercial studies were not automatically deemed at high risk. Studies 
were not rejected on subjective quality criteria other than study design different from RCTs or lack of ITT 
analysis. 
 
Bias across studies 
Bias(es) that may affect the cumulative evidence (publication, selective reporting, industry funding) were 
evaluated using contour enhanced and comparison-adjusted funnel plots (if >10 studies). The comparison-
adjusted funnel plot accounted for the fact that in network metanalysis each set of studies estimated a different 
summary effect. 
 
Qualitative analysis 
Data were extracted as dichotomous variables expressed as event rates in each arm. No studies were cluster 
randomized trials. The non-pertinent arm in multi-arm RCTs (e.g. placebo arm) was excluded. GRADE criteria 
were applied to rank the quality of each outcome (6). 
 
Statistical analysis 
Network metanalysis was undertaken if participants, treatments and clinical questions were deemed similar 
enough for meaningful data pooling. The network model was fit using commercial software (STATA/SE 15.0). 
Relative effect sizes were calculated as odds ratios (ORs) with 95% confidence intervals (CIs). We used a fixed 
effect model applying only inverse variance (I-V) weighting and a random-effects model weighting using the 
DerSimonian and Laird (D+L) model to account for heterogeneity. The surface under the cumulative ranking 
curve (SUCRA) probabilities were used to rank treatments.  
 
The network results were assessed for inconsistency and compared with pairwise metanalyses (applying both 
fixed effect and random effects models to evaluate heterogeneity). The percentage of variability attributable to 
heterogeneity was expressed by the I2 statistic.  
 
Sensitivity analysis was pre-specified to explore if results were sensitive to restriction to low risk of bias studies. 
A post-hoc analysis evaluated if results were sensitive to the time of treatment onset from the qualifying stroke. 
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Results 
 
Identification, eligibility and characteristics of the included studies 
The initial search (Table S2) identified 13,442 outputs. The study selection process (Figure 1) followed the 
PRISMA statement (7). After excluding 5 full-text studies (8-12), 16 RCTs (13-28) with 55,261 patients with 
previous ischaemic stroke/TIA as qualifying event were included. The number of study participants ranged from 
98 to 20,332. The treatment onset period ranged from <12h to 60 months (Table 1).  
 
Risk of bias within studies 
Six/18 trials were judged at overall low risk of bias, 5/18 at unclear risk, 5/18 at high risk of bias (Table S3).  
 
Bias across studies 
In the contour enhanced funnel plot (Figure S1-A) studies were missing in the middle and lower right area of 
non-significance, making publication bias or selective outcome bias plausible. The comparison-adjusted funnel 
plot (Figure S1-B) was asymmetric suggesting potential bias from small-study effects in the network.  
 
Qualitative review and pairwise metanalyses 
Seven/16 studies were short-term comparisons of DAPT vs monotherapy, 9/16 studies were long-term 
comparisons. There were no mid-term comparisons providing treatment effects between 3 months and 1 year. 
According to GRADE criteria (6), the quality of evidence was low for bleeding and moderate for all other 
outcomes.  
 
Recurrent stroke (Figure 2)  
Fourteen/16 trials reported on recurrent stroke. Two/16 (ESPRIT, CLAIR) used a combined outcome hence 
could not be included (Table 1). Short DAPT with aspirin clopidogrel was associated with decreased stroke 
recurrence compared to aspirin (OR 0.67, 95%CI 0.58-0.77; participants = 11,273; studies = 6). CIs were 
overlapping suggesting consistency (I2=0%). Long DAPT with aspirin clopidogrel was not more effective than 
clopidogrel (OR 0.98, 95%CI 0.83-1.14; participants = 7599; MATCH) and findings were only borderline 
significant for long DAPT with aspirin clopidogrel when compared to aspirin alone (OR 0.84, 95%CI 0.70-1.01; 
participants = 7,340; studies = 2). No better efficacy was seen for long aspirin dipyridamole compared to aspirin 
(OR 0.96, 95%CI 0.69-1.33; participants = 5,880; studies = 4) despite high heterogeneity (I2=64%), nor 
compared to clopidogrel (OR 1.02, 95%CI 0.93-1.12; participants = 20,332; PROFeSS). The stated pooled 
ORs were derived from a random-effects model given the likely genuine differences in treatment effects. 
 
Ischaemic stroke (Figure S2-A) 
Nine/16 trials reported on ischaemic stroke. Short aspirin clopidogrel significantly decreased ischaemic stroke 
compared to aspirin (OR 0.68, 95%CI 0.58-0.79; participants = 10,510; studies = 4; I2=0%). Long aspirin 
clopidogrel was more effective than aspirin (OR 0.79, 95%CI 0.65-0.96; participants = 7,340; studies = 2; 
I2=0%), but not more than clopidogrel (OR 0.92, 95%CI 0.79-1.08; participants = 7599; MATCH).   
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All bleeding (Figure S2-B) 
Fourteen/16 trials reported on all bleeding. Aspirin clopidogrel DAPT caused increased bleeding: the increase 
was 2.77-fold for long-term aspirin clopidogrel vs clopidogrel (OR 2.77, 95%CI 2.21-3.46; participants = 7599; 
MATCH), 2.25-fold for long-term aspirin clopidogrel vs aspirin (OR 2.25, 95%CI 1.97-2.57; participants = 7,340; 
studies = 2), 1.76-fold for short-term aspirin clopidogrel vs aspirin (OR 1.76, 95%CI 1.26-2.46; participants = 
11,178; studies = 6). The trials of aspirin dipyridamole did not report increased bleeding. 
 
Severe bleeding (Figure S2-C) 
Thirteen/16 trials reported on severe bleeding. Short aspirin clopidogrel was associated with a two-fold 
increase in severe bleeding compared to aspirin (OR 2.13, 95%CI 1.14-3.98; participants = 10,608; studies = 
3). The same was observed for long-term aspirin clopidogrel vs clopidogrel (OR 1.99, 95%CI 1.40-2.81; 
participants = 7599; MATCH). The other trials did not report increased severe bleeding. 
 
All-cause death, cardiovascular death, myocardial infarction (Figure S2-D E F) 
Thirteen/16 trials reported on all-cause death, 7 on cardiovascular death, 12 on myocardial infarction. No 
differences were shown for these outcomes. 
 
 
Network metanalysis 
There was one closed quadrilateral loop (aspirin - long-term aspirin clopidogrel - long-term aspirin dipyridamole 
- clopidogrel) (Figure 3).  
The comparison long-term aspirin dipyridamole vs aspirin had the largest contribution in the network (27.9%) 
(Figure S3). The difference between direct and indirect comparisons appeared small (ratio of odds ratio, ROR 
= 1.001, 95%CI 1.0-1.06) without inconsistency (Figure S4).  
 
The indirect comparison aspirin clopidogrel vs aspirin reduced recurrent stroke in the short-term (OR difference 
-0.03, 95%CI -0.04, -0.01) (Figure 4). The direction of effect was the same as in the direct comparisons, the 
entity was attenuated. For aspirin dipyridamole there was no benefit, also in keeping with direct comparisons. 
The indirect comparison between short-term and long-term DAPT, i.e. the main research question of this 
review, did not show evidence in favour of either treatment as the estimates’ CIs crossed the line of no effect, 
suggesting that hypothetical future studies might favour either short or long-term DAPT.  
 
According to the SUCRA hierarchy (Table 2, Figure 5), short-term aspirin clopidogrel displayed the best risk-
benefit profile with the best rank for reducing stroke (probability of 85.7%) and the 4th rank for avoiding all 
bleeding (37.9%). Long-term aspirin clopidogrel was 2nd for efficacy (40.4%) and worst for safety (98.0%). 
Clopidogrel was 3rd for efficacy (30.7%) but was ranked first to avoid severe bleeding (92.9%). 
 
Sensitivity analyses  
Studies at high or unclear risk of bias reported larger effect estimates and wider CIs (Figure S5-A). Patients 
started on DAPT within 48h of the qualifying stroke had lower recurrence of stroke (OR 0.72, 95%CI 0.60-0.86) 
compared to patients started at a later time (OR 0.92, 95%CI 0.80-1.06) (Figure S5-B). Random-effects 
univariate metaregression confirmed the association between recurrent stroke and treatment onset, which 
became borderline significant after adjusting for risk of bias in individual trials (Table S4). 
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Discussion 
 
Main findings 
This network metanalysis aimed to provide evidence-based hierarchies of the efficacy and safety of long-term 
and short-term DAPT with two drugs among aspirin, clopidogrel and dipyridamole for the secondary prevention 
of stroke in patients with previous stroke or TIA, using monotherapy with aspirin or clopidogrel as comparison. 
Although this study did not permit to strongly establish the superiority of a treatment over the other, short-term 
DAPT with aspirin clopidogrel had better risk-benefit profile (best for efficacy, 4th for safety) compared to long-
term aspirin clopidogrel (2nd for efficacy, worst for safety). Long-term monotherapy with clopidogrel alone 
appeared less effective than DAPT but safer (3rd for efficacy, best for safety against severe bleeding).  
 
Broader landscape 
A strength of network metanalysis is the ability to combine direct and indirect evidence about the treatments 
under evaluation. Previous studies selectively looked at either the short-term or long-term efficacy of anti-
platelet treatments. Concerning short-term efficacy, a metanalysis by Wong et al. (29) including 14 RCTs and 
9012 patients reported that DAPT was more effective than monotherapy in reducing stroke recurrence in 
patients with a qualifying stroke in the previous 72hrs, in keeping with this study. A pairwise metanalysis by 
Hao et al. (30) included 3 RCTs and 10447 patients, who were given either DAPT with aspirin clopidogrel or 
aspirin within 24hrs from the qualifying stroke and were followed-up for 3 months. This study too found that 
DAPT was more effective than monotherapy in preventing recurrent stroke especially within 21 days of 
randomisation.  
Concerning long-term efficacy, a metanalysis by Lee et al. (31) of 7 RCTs and 39,574 patients reported that 
DAPT lasting more than 1 year was not associated with reduced risk of recurrent stroke but with higher risk of 
bleeding compared with clopidogrel in monotherapy. 
A network metanalysis by Xie et al. (32) compared several long-term antiplatelet treatments, in the form of 
DAPT and monotherapy. In that study, long-term DAPT with aspirin clopidogrel was ranked the best type of 
DAPT and outperformed long-term aspirin dipyridamole, in keeping with this study. In contrast to this study, Xie 
et al. (32) did not evaluate short-term DAPT and included long-term treatment with a larger number of 
monotherapy drugs. Particularly trials of cilostazol were included, a drug licensed in China and East Asia but 
not in the US and Europe. The efficacy and safety of cilostazol were tested in East Asian patients, a group at 
increased risk of stroke, but not in Western populations. The excellent efficacy of cilostazol found by Xie et al. 
(32) was not generalizable to other populations and countries therefore was not included in this review. 
A pairwise metanalysis by Zhang et al. (33) included 8 RCTs and 20,728 patients. DAPT with aspirin 
clopidogrel was stratified according to short- or long-term duration. Long-term DAPT was not more effective 
than short-DAPT in the prevention of stroke. The pairwise metanalyses and treatment ranking performed in the 
present study updated, extended and confirmed the findings by Zhang et al. (33). 
 
Assumptions and limitations 
This study had limitations calling for caution in interpretation. Some may be related to clinical assumptions, 
definitions and consequent heterogeneity. Some limitations may be due to biases.  
We made two important assumptions. Firstly, this review included short-term effects of short-term treatments 
derived from short follow-up studies and compared them with long-term effects of long-term treatments derived 
from long follow-up studies. Long follow-up studies in patients receiving short-term treatment were unavailable. 
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While this review aimed to overcome such a constraint due to the unavailability of directly observed data, 
findings should be interpreted with caution.   
Secondly, this review focused on comparing short-term vs long-term DAPT. Monotherapy was assumed inferior 
to DAPT, in keeping with contemporary clinical practice (1). Previous metanalyses (29, 34) suggested that it 
was the number of drugs (in terms of two drugs vs one - not which one) to determine efficacy. This study did 
not compare monotherapies between themselves or long vs short monotherapy. Studies were coded based on 
short or long DAPT duration, drug combination (among aspirin, clopidogrel, dipyridamole) and monotherapy 
drug used as comparison (either aspirin or clopidogrel). The duration of the latter (which depended on trial’s 
follow-up period) was not coded. This allowed the formation of one closed loop in the network.  
We also acknowledge some potential bias(es). Studies at high or unclear risk of bias reported higher effect 
estimates. Publication bias appeared plausible, although it did not occur more often in commercial studies. 
Spuriously inflated effects in small studies, heterogeneity according to study size (e.g., intervention more 
intense, patients sicker in small studies), artefacts or chance may also have caused bias (35).  
The time of treatment onset was a likely explanation for heterogeneity. While some studies had instated DAPT 
within 48h of the qualifying stroke, leading to better efficacy in stroke prevention, some had lenient inclusion 
criteria and allowed treatment to be instated in participants up to 60 months after the qualifying stroke.  
Despite relatively narrow age range (63-70 years), differences in trial populations could not be excluded. The 
studies’ publication dates spanned from 1983 to 2018. Some studies had geographic origin which may have 
conferred increased risk (e.g., JASAP was a Japan-only study). It was plausible that definitions for clinical 
events and states for patients, determining eligibility and outcomes, varied over time or were applied more or 
less stringently. It is exemplary that much less heterogeneity was found for outcomes such as “myocardial 
infarction” compared to “bleeding” for instance, as the definition of “bleeding” could have been less 
standardized in the different studies. The dose of certain medications (notably aspirin) varied, also reflecting 
changes over four decades. Changes in treatment of important comorbidities may have played a role as effect 
modifier, for instance more intense uptake of statins and anti-hypertensive drugs with effect on cardiovascular 
events. 
In this network metanalysis there was one quadrilateral loop and two edges consisted of single studies. The 
high contribution to the network by aspirin dipyridamole vs aspirin trials may be suboptimal. The inclusion of 
clopidogrel vs aspirin trials would introduce closed triangular loops which may lend balance and strength to the 
network, potentially making it more informative. Comparing monotherapies however was not of primary interest 
in this work. 
 
Policy implication and future perspective 
This study is not a call for clinicians and policy making bodies to change clinical practice and practice 
guidelines. Short-term DAPT remains the recommended first choice for the secondary prevention of stroke. 
Although evidence was of mixed quality, long-term DAPT with aspirin clopidogrel was ranked worse. Whether 
the same findings would be generalizable to other populations or groups, e.g. very high-risk patients, patients 
at increased risk of bleeding, elderly patients over 80 years, diabetic patients, etc. was not answered by this 
review. The call for clinicians to make decisions based on an individual patient’s needs, prioritizing stroke 
prevention or avoidance of bleeding probably remains appropriate in light of these findings.  
A prospective RCT comparing long vs short-term DAPT may be onerous and clinically not justified in light of 
these findings. Likely, ongoing antiplatelet treatment studies harvesting pharmacogenomics data (CYP450, 
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genes involved in platelet reactivity etc.) will offer insights to improve the prioritization of treatment regimen in 
each patient (“personalised medicine”) based on their individual risk profile.  
 
 
 
Conclusion 
This study showed that DAPT in secondary prevention for stroke offered the best protection over monotherapy 
in the first 3 months, at the expense of increased risk of bleeding. This strategy appeared superior compared to 
the continuation of DAPT beyond the first 3 months, when monotherapy with clopidogrel had acceptable 
efficacy but better protection from severe bleeding. 
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Figure legends 
 
 
 
Figure 1. Study selection process 
 
 
 
Figure 2. Pairwise metanalyses for recurrent stroke (primary efficacy outcome) by treatment comparisons 
addressed in the included studies 
 
Fixed effect metanalysis with inverse variance (I-V) weighting and random-effects metanalysis applying the 
DerSimonian and Laird (D+L) model were reported. The percentage of variability across studies attributable to 
heterogeneity was expressed by the I2 statistic. Given the low power of the method, data were considered 
heterogenous if p was less than 0.10. An I2 statistic of 0% to 25% might not be important, 25 to 50% may represent 
moderate heterogeneity, 50% and above indicates considerable heterogeneity.  
 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; OR odds ratio 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C) 
 
 
 
Figure 3. Network plot of treatment comparisons for recurrent stroke (primary efficacy outcome) 
 
The quantity and quality of evidence are shown through weighting and colouring.  
The size of the nodes and the thickness of the edges correspond to the number of studies addressing each direct 
comparison (total for this outcome n = 14): 
AC short vs A = 6 studies 
AC long vs A = 2 studies 
AC long vs C = 1 study 
AD long vs A = 4 studies 
AD long vs C = 1 study 
 
The colour of the edges represents the mean overall risk of bias in the corresponding comparison (green = low risk 
of bias; yellow = some concerns/unclear risk of bias).  
 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole 
 
Two studies (ESPRIT, CLAIR) reported on several outcomes of interest but not on recurrent stroke.  
The network for all outcomes (total n = 16) included the following: 
AC short vs A = 7 studies 
AC long vs A = 2 studies 
AC long vs C = 1 study 
AD long vs A = 5 studies 
AD long vs C = 1 study 
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Figure 4. Estimated differences in treatment effect (OR difference) for recurrent stroke (primary efficacy outcome) 
from network metanalysis (interval plot) 
 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole 
 
 
 
 
Figure 5. Cumulative probability and probability of SUCRA ranking curves for all outcomes. Also refer to Table 2. 
 
 
 
 
Supplemental figure legends 
 
 
Figure S1-A B. Bias across studies 
 
A funnel plot is a scatterplot of the study effect size versus a measure of its precision. In order to extend the use 
funnel plots in network meta-analysis, we accounted for estimate effects that were derived from different sets of 
comparisons. All observed sets of comparisons were reported (36). 
The contour enhanced funnel plot (A) showed studies were missing in the middle and lower right area of non-
significance, making publication bias or selective outcome bias plausible. Asymmetry of the comparison-adjusted 
funnel plot (B) also suggests potential bias from small-study effects in the network. 
 
 
 
 
Figure S2-A. Pairwise metanalyses for ischaemic stroke by treatment comparisons addressed in the included 
studies 
 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; OR odds ratio; I-V inverse variance 
weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C) 
 
 
 
Figure S2-B. Pairwise metanalyses for all bleeding by treatment comparisons addressed in the included studies 
 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C)  
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; OR odds ratio; I-V inverse variance 
weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
 
 
 
Figure S2-C. Pairwise metanalyses for severe bleeding by treatment comparisons addressed in the included 
studies 
 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C)  
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Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; OR odds ratio; I-V inverse variance 
weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
 
 
 
Figure S2-D. Pairwise metanalyses for all-cause death by treatment comparisons addressed in the included 
studies  
 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C)  
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; OR odds ratio; I-V inverse variance 
weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
 
 
 
Figure S2-E. Pairwise metanalyses for cardiovascular death by treatment comparisons addressed in the included 
studies  
 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C)  
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; OR odds ratio; I-V inverse variance 
weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
 
 
 
Figure S2-F. Pairwise metanalyses for myocardial infarction by treatment comparisons addressed in the included 
studies  
 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C)  
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; OR odds ratio; I-V inverse variance 
weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
 
 
 
Figure S3. Contribution plot for recurrent stroke (primary efficacy outcome) in the network 
 
The size of the squares is proportional to the percent contribution of the direct comparison defining the column, to 
the network estimate of the row  
 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole 
 
 
 
Figure S4. Difference between direct and indirect effect estimates for recurrent stroke in the quadrilateral loop in 
the network (aspirin – long-term aspirin clopidogrel – long term aspirin dipyridamole – clopidogrel) (inconsistency 
plot). The included treatment comparisons did not provide closed triangular loops. 
 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; ROR ratio of odds ratios 
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Figure S5-A. Sensitivity analysis for recurrent stroke (primary efficacy outcome). Pairwise metanalysis by risk of 
bias at the study level 
Abbreviations: OR odds ratio; I-V inverse variance weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C) 
 
 
 
Figure S5-B. Sensitivity analysis for recurrent stroke (primary efficacy outcome). Pairwise metanalysis by time of 
treatment onset since qualifying stroke event 
Abbreviations: OR odds ratio; I-V inverse variance weighting (fixed effect model); D+L DerSimonian and Laird weighting (random-effects model) 
Note: intervention = DAPT (AC or AD); control = monotherapy (A or C) 
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Tables 
 
Table 1. Characteristics of the included studies  
 
Serial Study ID Population Comparison N per arm Mean age Follow-up Onset  Dose RCT features Funding 
1 
AICLA 1983 
(1) 
TIA/ischaemic stroke A vs AD 198/202 63/63 36 months 12 months  A (3x300mg) vs [A (3x300mg) + D (3x75mg)] 
Double blind, multiarm, loss to F/U 11%, 
ITT 
Boehringer-
Ingelheim 
2 
ACCSG 
1985 (2) 
TIA A vs AD 442/448 63 25 months* 3 months  A (4x325mg) vs A (4x325mg) + D (4x75mg) Double blind, loss to F/U 4%, ITT 
Boehringer-
Ingelheim 
3 
ESPS2 1996 
(3) 
TIA/ischaemic stroke A vs AD 1649/1650 67/67 24 months 3 months  A (2x25mg) vs [A (2x25mg) + D (2x200mg)] 
Double blind, multiarm, loss to F/U 
0.64%, ITT 
Boehringer-
Ingelheim 
4 
MATCH 
2004 (4) 
TIA/ischaemic stroke AC vs C 3979/3802 66/66 18 months 3 months  [A (75mg) + C (75mg)] vs C (75mg) Double blind, loss to F/U 4%, ITT 
Sanofi, Bristol 
Myers-Squibb 
5 
CARESS 
2005 (5) 
TIA/stroke and >=50% 
carotid stenosis (Doppler) 
AC vs A 51/56 66/63 0.25 month 3 months  [A (75mg) + C (75mg)] vs A (75mg) 
Double blind, loss to F/U 0% for 
extracted endpoint, ITT 
Sanofi, Bristol 
Myers-Squibb 
6 
ESPRIT 
2006 (6) 
TIA/ischaemic stroke AD vs A 1363/1376 63/63 42 months 6 months  A [(30 to 325mg) + D (2x200mg)] vs A (30 to 325mg) 
Not blinded, open label, multiarm, loss 
to F/U <1%, ITT/post-hoc  
non-commercial 
7 
FASTER 
2007 (7) 
TIA/ischaemic stroke AC vs A 98/95 69/70 3 months 24 hours  A [(81mg) + C (75mg)] vs A (81mg) 
Double blind, multiarm, loss to F/U <1%, 
ITT 
non-
commercial/Astra 
8 
PROFeSS 
2008 (8) 
Ischaemic stroke AD vs C 10181/10151 66/66 30 months 6 months  A [2x25mg) + D (2x200mg)] vs C (75mg) Double blind, loss to F/U 0.6%, ITT 
Boehringer-
Ingelheim 
9 
CLAIR 2010 
(9) 
TIA/stroke and >=50% 
carotid stenosis(Doppler)  
AC vs A 47/53 59/56 0.25 month 7 days  [A (75 to 160mg) + C (75mg)] vs A (75 to 160mg) 
Single blind, open label, blinded 
endpoint, loss to F/U 10%, modif ITT 
non-commercial 
10 
CHARISMA 
2011 (10) 
TIA/ischaemic stroke AC vs A 2157/2163 65/65 25 months a 60 months  [A (75 to 162mg) + C (75mg)] vs A (75 to 162mg) Double blind, loss to F/U not stated, ITT Sanofi 
11 
JASAP 2011 
(11) 
Ischaemic stroke AD vs A 655/639 66/66 15 months 
6 months to 
1 week 
A [2x25mg) + D (2x200mg)] vs A (81mg) Double blind, loss to F/U <1%, ITT 
Boehringer-
Ingelheim 
12 
SPS3 2012 
(12) 
Ischaemic stroke AC vs A 1517/1503 63/63 41 months a 6 months  [A (325mg) + C (75mg)] vs A (325mg) Double blind, loss to F/U 13%, ITT non-commercial 
13 
CHANCE 
2013 (13) 
TIA/ischaemic stroke AC vs A 2584/2586 63/62 3 months 24 hours  A [(75 to 300mg) b + C (75mg)] vs A (75 to 300mg) 
Double blind, loss to F/U 6% and 7%, 
ITT 
non-commercial 
14 
Yi X, 2014 
(14) 
Ischaemic stroke AC vs A 284/286 70/70 1 month 48 hours  A [(200mg) c + C (75mg)] vs A (200 to 100mg) 
Blinding not specified, loss to F/U <1%, 
ITT 
non-commercial 
15 
COMPRESS 
2016 (15) 
Ischaemic stroke (CT or 
MRI) 
AC vs A 174/178 68/67 1 month 48 hours  [A (100mg) + C (75mg)] vs A (100mg) Double blind, loss to F/U about 7%, ITT 
Sanofi,Bristol 
Myers-Squibb 
16 
POINT 2018 
(16) 
TIA/ischaemic stroke AC vs A 2432/2449 65/65 3 months 12 hours  A [(50 to 325mg) + C (75mg)] vs A (50 to 325mg) Double blind, loss to F/U about 7%, ITT non-commercial 
 
a median follow-up 
b A in combination treatment suspended after day 21 and replaced with placebo  
c A in combination treatment suspended after day 30 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole  
NOTE: Daily aspirin doses varied from 50 to 1300mg. The daily dose of clopidogrel was 75mg. Daily dipyridamole doses varied from 225 to 400mg 
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Table 1 (continued). Characteristics of the included studies 
 
Serial Study ID Recurrent stroke Ischaemic stroke All-cause death CV death MI All bleeding Severe bleeding 
Moderate/mild 
bleeding 
1 
AICLA 1983 
(1) 
A 17/198; AD 18/202 nr A 10/198; AD 11/202 nr A 4/198; AD 3/202 A 7/198; AD 6/202 A 2/198; AD 1/202 A 5/198; AD 7/202 
2 
ACCSG 
1985 (2) 
A 60/442; AD 53/448 nr A 38/442; AD 46/448 nr A 23/442; AD 25/448 A 32/442; AD 30/448 A 6/442; AD 2/448 A 26/442; AD 28/448 
3 
ESPS2 1996 
(3)  
A 206/1649; AD 157/1650 nr 
A 182/1649;  
AD 185/1650 
nr A 39/1649; AD 35/1650 A 135/1649; AD 144/1650 A 20/1649; AD 27/1650 
A 115/1649;  
AD 117/1650 
4 
MATCH 
2004 (4) 
AC 339/3797; C 347/3802 AC 309/3797; C 333/3802 
AC 201/3797;  
C 201/3802 
AC 124/3797;  
C 121/3802 
AC 73/3797; C 68/3802 AC 289/3797; C 110/3802 AC 96/3797; C 49/3802 
AC 193/3797;  
C 61/3802 
5 
CARESS 
2005 (5) 
AC 5/51; A 12/56 AC 0/51; A 4/56 nr nr AC 1/51; A 0/56 AC 2/51; A 1/56 AC 0/51; A 0/56 AC 2/51; A 1/56 
6 
ESPRIT 
2006 (6) 
nr AD 96/1363; A 116/1376 AD 93/1363; A 107/1376 AD 44/1363; A 60/1376 nr nr AD 35/1363; A 53/1376 nr 
7 
FASTER 
2007 (7) 
AC 5/98; A 9/95 nr nr nr nr nr nr nr 
8 
PROFeSS 
2008 (8) 
AD 916/10181;  
C 898/10151 
nr 
AD 739/10181;  
C 756/10151 
AD 435/10181;  
C 459/10151 
AD 178/10181;  
C 197/10151 
AD 535/10181;  
C 494/10151 
AD 419/10181;  
C 365/10151 
nr 
9 
CLAIR 2010 
(9) 
nr nr AC 0/46; A 0/52 nr nr AC 2/46; A 0/52 AC 0/46; A 0/52 AC 2/46; A 0/52 
10 
CHARISMA 
2011 (10) 
AC 105/2157; A 131/2163 AC 91/2157; A 114/2163 nr AC 56/2157; A 72/2163 AC 43/2157; A 32/2163 AC 807/2157; A 444/2163 AC 41/2157; A 37/2163 AC 51/2157; A 24/2163 
11 
JASAP 2011 
(11) 
AD 57/652; A 39/639 AD 45/652; A 32/639 AD 4/652; A 10/639 nr nr AD 192/652; A 187/639 AD 26/652; A 24/639 AD 166/652; A 163/639 
12 
SPS3 2012 
(12) 
AC 125/1517; A 138/1503 AC 100/1517; A 124/1503 AC 113/1517; A 77/1503 nr AC 31/1517; A 38/1503 AC 105/1517; A 56/1503 nr nr 
13 
CHANCE 
2013 (13) d 
AC 212/2584; A 303/2586 AC 204/2584; A 295/2586 AC 10/2584; A 10/2586 AC 6/2584; A 5/2586 AC 3/2584; A 2/2586 AC 60/2584; A 41/2586 AC 4/2584; A 4/2586 AC 33/2584; A 23/2586 
14 
Yi X, 2014 
(14) e 
AC 5/284; A 18/286 nr AC 2/284; A 2/286 nr AC 3/284; A 3/286 AC 16/284; A 15/286 nr nr 
15 
COMPRESS 
2016 (15) 
AC 3/174; A 5/178 AC 2/174; A 5/178 AC 3/174; A 0/178 AC 1/174; A 0/178 AC 0/174; A 1/178 AC 29/174; A 19/178 AC 7/174; A 2/178 AC 22/174; A 17/178 
16 
POINT 2018 
(16) 
AC 116/2432; A 156/2449 AC 112/2432; A 155/2449 AC 18/2432; A 12/2449 AC 6/2432; A 4/2449 AC 10/2432; A 7/2449 AC 61/2432; A 22/2449 AC 21/2432; A 9/2449 AC 40/2432; A 13/2449 
 
Intention-to-treat (ITT) samples used for all outcomes 
Abbreviations: A aspirin; C clopidogrel; D dipyridamole; AC aspirin clopidogrel; AD aspirin dipyridamole; nr not reported 
d CHANCE 2103 and CHANCE 2015 were protocol pre-specified analyses at 3 months and 12 months follow-up, although treatment did not continue beyond 3 months (CHANCE 2015 not included) 
e Yi 2014 and Wang 2015 were analyses at 1 month and 6 months follow-up, although treatment did not continue beyond 1 month (Wang 2015 not included) 
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Table 2. Estimated SUCRA probabilities of treatments on primary (efficacy) and secondary (efficacy and 
safety) outcomes 
 
SUCRA was expressed as a percentage probability that a treatment was ranked first for its efficacy on the 
outcome, where 100% implies a treatment is certain to be the best, and 0% implies a treatment is certain to 
be the worst. 
 
 
Treatment 
Outcome & rank Aspirin Clopidogrel 
Short-term 
aspirin 
clopidogrel 
Long-term 
aspirin 
clopidogrel 
Long-term  
aspirin 
dipyridamole 
Recurrent stroke (primary outcome)     
Best 0.0 6.3 85.7 5.8 2.2 
2nd 3.2 24.7 9.9 40.4 21.8 
3rd 12.3 30.7 3.2 27.1 26.7 
4th 23.3 21.7 1.2 20.4 33.6 
Worst 61.3 16.6 0.1 6.4 15.6 
Ischaemic stroke      
Best 0.0 9.9 77.4 11.3 1.4 
2nd 2.0 17.7 14.5 52.9 12.9 
3rd 15.9 32.5 7.6 28.9 15.1 
4th 47.2 16.8 0.5 6.1 29.4 
Worst 34.9 23.0 0.0 0.9 41.2 
All bleeding      
Best 40.9 17.7 11.9 0.0 29.4 
2nd 37.7 13.3 19.7 0.0 29.3 
3rd 18.6 21.8 29.7 0.1 29.9 
4th 2.8 46.1 37.9 1.9 11.3 
Worst 0.0 1.1 0.8 98.0 0.1 
Severe bleeding      
Best 0.5 92.9 0.6 0.2 5.8 
2nd 9.3 5.9 5.2 6.3 73.3 
3rd 53.1 1.0 13.5 18.6 13.8 
4th 31.9 0.3 38.2 23.7 5.8 
Worst 5.2 0.0 42.4 51.1 1.3 
All-cause death      
Best 20.5 7.9 9.2 2.8 59.5 
2nd 36.7 21.4 22.7 3.2 16.0 
3rd 26.4 12.1 34.2 7.0 20.3 
4th 13.1 49.3 24.1 10.2 3.3 
Worst 3.3 9.3 9.7 76.8 0.8 
Cardiovascular death      
Best 0.7 11.8 0.2 18.6 68.7 
2nd 1.4 52.1 1.2 23.4 21.8 
3rd 4.0 31.3 2.8 53.7 8.3 
4th 70.4 2.3 25.1 1.5 0.6 
Worst 23.4 2.6 70.6 2.8 0.6 
Myocardial infarction      
Best 19.1 8.4 6.8 5.6 60.2 
2nd 24.3 35.2 18.6 8.3 13.6 
3rd 27.1 13.0 22.0 22.6 15.4 
4th 24.7 24.1 26.3 17.0 7.9 
Worst 4.9 19.3 26.4 46.6 2.9 
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Supplemental material 
 
 
Table S1. Definitions 
 
 
 
Recurrent stroke 
(primary efficacy 
outcome) 
 
New extracranial, intracranial, lacunar, retinal infarction of ischaemic and 
haemorrhagic origin; presenting with sudden onset of neurological deficit and/or 
CT/MR imaging evidence of infarction, not attributable to other cause (tumour, 
seizure, brain infection, metabolic disease or degenerative neurologic disease); 
fatal and nonfatal; disabling and non-disabling 
 
 
Ischaemic stroke 
 
As above with exclusion of haemorrhagic cause i.e. acute extravasation of 
blood into the brain parenchyma or subarachnoid space 
 
 
All bleeding 
 
Bleeding from all causes, including cranial and extracranial (gastrointestinal, 
haematuria), regardless of severity also including minor bleeding (e.g. 
nosebleed); disabling and non-disabling 
 
 
Severe bleeding 
 
Intracranial or ocular haemorrhage or other haemorrhage causing 
hemodynamic compromise requiring blood or fluid replacement, or inotropic 
support or surgery, or hospitalization, or prolongation of an existing 
hospitalization; disabling and non-disabling 
 
 
All-cause death 
 
Death during follow-up from any cause 
 
 
Cardiovascular death 
 
Death due to stroke (ischaemic and haemorrhagic), systemic haemorrhage, 
myocardial infarction, heart failure, pulmonary emboli, sudden cardiac death, 
arrhythmia 
 
 
Myocardial infarction 
 
Clinical/ECG/biomarker diagnostic criteria 
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Table S2. Search strategy 
 
  Results 
 
  MEDLINE 
(Ovid) 
EMBASE 
(Ovid) 
PubMed Cochrane 
Library 
database 
Clinical 
Trials.gov 
Item Searches      
1 aspirin 62653 205065 62704 12154 1278 
2 exp ASPIRIN 42485 na na 5635 na 
3 clopidogrel 12821 54774 12849 4729 835 
4 Plavix 285 3151 na 116 na 
5 dipyridamole 10229 25028 10261 1359 85 
6 acetyl salicylic acid 763 na 923 181 1278 
7 dual antiplatelet 3784 8771 4342 1217 193 
8 aspirin-dipyridamole 258 310 2322 121 12 
9 Aggrenox 38 334 51572 35 10 
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
or 9 
78174 236177 78601 15963 3691 
11 exp STROKE 114897 383165 290361 8879 4206 
12 stroke 251218 171225 na 56425 na 
13 cerebrovascular accident 4062 170345 293234 8461 na 
14 exp Cerebral Infarction 29404 67206 46253 980 567 
15 cerebral infarction 28211 19721 na 4310 na 
16 transient ischaemic attack 1640 2574 24979 1887 96 
17 11 or 12 or 13 or 14 or 15 or 16 278055 473955 312370 59135 4869 
18 randomised 90083 132048 90010 123446 11006 
19 randomized 746910 954038 815370 794090 148534 
20 exp Randomized Controlled 
Trials as Topic 
119424 148543 607016 23124 15301 
21 18 or 19 or 20 777969 1006235 846007 835589 174841 
22 10 and 17 8206 34116 8855 4039 193 
23 21 and 22 2524 6893 2651 2324 168 
24 limit 23 to (English language and 
humans) 
2139 6351 2460 2324 168 
 
Note: Search criteria were centred on three main areas/MeSH terms: anti-platelet aggregation, stroke and study 
design as randomised controlled trial. Logical operators (‘or’, ‘and’) were used to combine search outputs. First we 
summed all outputs within each of these three areas (‘or’); then we selected outputs at the intersection between the 
three areas (‘and’). 
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Table S3. Within-study risk of bias assessment  
 
 
 
 
Note: Each domain was scored as low, high or uncertain/some concerns, where low indicated that the study was less open 
to bias. A study was judged at low risk of bias if all domains were at low risk. A study was judged at high risk if one or more 
domains were at high risk. A study was judged at unclear risk/some concerns if one or more raised some concerns.  
 Overall bias and funding: Six/16 trials were judged at overall low risk of bias, 3/6 were commercially funded. Five/16 trials 
were judged at unclear risk of bias, 4/5 had commercial funding. Five/16 trials were judged at high risk of bias, 2/5 were 
commercial.  
 Allocation: All RCTs allegedly used a random sequence generation; 4/16 studies however raised concerns or reported 
insufficient data. 
 Blinding: Two/16 studies were open label; 2/16 did not specify blinding. The other studies were double blinded. 
 Incomplete outcome data: Two/16 studies did not specify reasons for withdrawals, losses to follow-up and protocol 
deviations. 
Selective reporting: In 2/16 studies, although the primary outcomes were reported as per protocol, the secondary outcomes 
appeared selected. 
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Table S4. Random-effects metaregression between recurrent stroke (primary efficacy outcome) and 
treatment onset (univariate), and between recurrent stroke and treatment onset as well as risk of bias at 
study level (multivariate).  
 
 
OR Coefficient 95% CI Standard error t p 
 
Univariate 
Onset 0.0576 0.00455 0.111 0.0244 2.37 0.036 
Constant 0.604 0.334 0.875 0.124 4.87 0.000 
 
Multivariate  
Onset 0.0537 -
0.000873 
0.108 0.0248 2.17 0.053 
Risk of bias 0.101 -0.0915 0.294 0.0876 1.16 0.272 
Constant 0.503 0.166 0.839 0.153 3.29 0.007 
 
OR: odds ratio 
Onset: time of treatment onset from qualifying stroke 
Risk of bias: assessed in individual studies using RoB2.0 tool 
 
